Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors (Q33621243)

28 July 2017

Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors (English)

1 reference

28 July 2017

1 reference

ChEBI release 2020-05-28

M A Dickson

1

1 reference

28 July 2017

S H Okuno

2

1 reference

28 July 2017

M L Keohan

3

1 reference

28 July 2017

R G Maki

4

1 reference

28 July 2017

D R D'Adamo

5

1 reference

28 July 2017

T J Akhurst

6

1 reference

28 July 2017

C R Antonescu

7

1 reference

28 July 2017

G K Schwartz

8

1 reference

28 July 2017

16 August 2012

1 reference

28 July 2017

1 reference

28 July 2017

24

1 reference

28 July 2017

252-257

1 reference

28 July 2017

1

1 reference

An investigation into the potential use of serum Hsp70 as a novel tumour biomarker for Hsp90 inhibitors

28 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023320

BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023320

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023320

Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023320

The lessons of GIST--PET and PET/CT: a new paradigm for imaging

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023320

Gastrointestinal stromal tumour.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023320

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023320

Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023320

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023320

Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations

21 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS275

BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS275

Identification of new biomarkers for clinical trials of Hsp90 inhibitors

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22898035

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/ANNONC/MDS275

1 reference

28 July 2017

1 reference

28 July 2017

1 reference